Curetis Announces Participation in Major Investor and Scientific Conferences in the Second Quarter 2017
Amsterdam, the Netherlands, and Holzgerlingen, Germany, March 29, 2017 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company will attend several major industry conferences in the second quarter of 2017. The respective presentations will be made available on the company’s website.
10th Kempen Life Science Day, April 19, 2017 – Amsterdam, The Netherlands: company presentation and one-on-one meetings.
27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25, 2017 – Vienna, Austria: exhibition booth in Hall B, booth 20; sponsored symposium “Detect to cure – superbugs in various healthcare settings. Diagnostic approaches to win the challenge”, Saturday, April 22, 01:30pm CET, Hall E.
ATS International Conference, May 19-24, 2017 – Washington DC, USA: exhibition booth 1206 and KOL meetings.
Donau Invest GmbH / Advantage Strategy & Finance – Family Office Pharma & Biotech Day, May 31, 2017 – Vienna, Austria: company presentation and Q&A session.
ASM Microbe 2017, June 1-5, 2017 – New Orleans, LA, USA: exhibition booth 2941 and oral presentation of Unyvero LRT clinical trial data.
goetzpartners Healthcare Day, June 29, 2017 – London, UK: one-on-one meetings and panel discussion.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
International Media & Investor Inquiries
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Tel. +1 646 536 7012
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/940ec27d-b441-413d-ae6d-69c9a809a427